このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

記憶を改善するための刺激 (STIM)

2026年6月29日 更新者:Benjamin Hampstead, PhD、University of Michigan

軽度認知障害の治療としての高解像度経頭蓋直流刺激 (HD-tDCS) のテスト

この研究では、軽度認知障害 (MCI) およびアルツハイマー型認知症 (DAT) の個人の治療のための非侵襲的な脳刺激の形式のさまざまな用量の効果をテストします。

調査の概要

詳細な説明

この調査研究は、軽度認知障害 (MCI) およびアルツハイマー型認知症 (DAT) の脳機能に対する弱い電気刺激の影響に関する重要な情報を学ぶために行われています。 この調査結果は、記憶力と思考力を高めるために「どれだけの」刺激が必要か、それが脳機能にどのように影響するか、そして誰が最も恩恵を受ける可能性があるかを判断するのに役立ちます. 最終的に、この情報は、アルツハイマー病のさまざまな段階にある人々の治療努力の指針となる可能性があります。 この研究では、脳画像を使用して、これらの治療が参加者の学習方法や情報の記憶方法を変えるかどうかを確認します。 機能的磁気共鳴画像法 (fMRI) および陽電子放出断層撮影法 (PET) スキャンが使用されます。 この研究では、認知テストとアンケートを使用して、参加者の記憶 (および関連する能力) が治療によって変化するかどうかも調べます。 この研究では、MCIまたはDATと診断された参加者を登録します。 参加者がミシガン大学の記憶と老化プロジェクト (UM-MAP; HUM00000382) に共同登録されることが期待されますが、必須ではありません。

研究の種類

介入

入学 (実際)

233

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Michigan
      • Ann Arbor、Michigan、アメリカ、48105
        • University of Michigan

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

55年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

説明

包含基準:

  1. 軽度認知障害(MCI)またはアルツハイマー型認知症(DAT)の診断
  2. MRI 対応である必要があり、高精細経頭蓋直流刺激 (HD-tDCS; 上半身または頭部に金属または電子インプラントがないなど) にも適用される基準
  3. -研究登録前の少なくとも4週間、関連する薬物療法で安定している

除外基準:

  1. 特定の神経疾患
  2. 特定の精神状態
  3. 重度の感覚障害

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
偽コンパレータ:シャム刺激
HD-tDCS 治療の偽 (プラセボ) 用量を 30 分間、5 ~ 30 セッションの間。
参加者は、偽 (プラセボ) HD-tDCS を 30 分間、5 ~ 30 セッションで受け取ります。
実験的:1 mA 投与刺激
HD-tDCS 治療の 1 ミリアンペアの用量を 30 分間、5 ~ 30 セッションの間。
参加者は、5 ~ 30 セッションの間、30 分間 1 mA で HD-tDCS を受け取ります。
実験的:2 mA 投与刺激
HD-tDCS 治療の 2 ミリアンペア線量を 30 分間、5 ~ 30 セッションの間。
参加者は、5 ~ 30 セッションの間、30 分間 2 mA で HD-tDCS を受け取ります。
実験的:3 mA 投与刺激
HD-tDCS 治療の 3 ミリアンペアの用量を 30 分間、5 ~ 30 セッションの間。
参加者は、5 ~ 30 セッションの間、30 分間 3 mA で HD-tDCS を受け取ります。

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Lateral Temporal Cortex Connectivity
時間枠:Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Primary outcome focuses on default mode network (DMN) between-network functional connectivity because the lateral temporal cortex is a core component of the DMN. Between-network functional connectivity is estimated from fMRI data as strength of temporal coupling between the DMN and other high-level (association) brain networks. For each participant and time point, correlation-based connectivity (Pearson r; Fisher r-to-z transformed; arbitrary units) computed between DMN regions and other regions of the association cortex defined using standard functional atlas. Higher values reflect stronger functional connectivity between DMN and other regions. A Z-score's range is infinite. Expected value is between -3 to 3. Analyses conducted separately for amyloid negative (A-) and amyloid positive (A+) participants. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

二次結果の測定

結果測定
メジャーの説明
時間枠
Self-Report of Contentment With Memory
時間枠:Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

The Multifactorial Memory Questionnaire (MMQ) consists of three scales measuring separate aspects of metamemory. Items are rated on a 5-point Likert scale (0-4) based on the test taker's experiences over the previous two weeks.

MMQ-Satisfaction (formerly called MMQ-Contentment) scale measures satisfaction, concern, and overall appraisal of one's own memory. Each of 18 statements is rated based on degree of agreement. The score range is 0 to 72, with higher scores indicating a higher degree of satisfaction.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Self-Report of Memory Mistakes
時間枠:Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Multifactorial Memory Questionnaire (MMQ) Ability Score - This scale measures self-perception of everyday memory ability. Respondents rate how often they experienced each of 20 common memory mistakes over the previous two weeks. The score range is 0 to 80, with higher scores indicating better self-reported memory ability.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Self-Report of Memory Strategies Used
時間枠:Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Multifactorial Memory Questionnaire (MMQ) Strategies Score - This scale measures the use of practical memory strategies and aids in day-to-day life. Respondents rate how often they used each of 19 memory strategies over the previous two weeks. The score range is 0 to 76, with higher scores indicating greater use of memory strategies.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Change in Memory Functioning
時間枠:Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
The Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) is a comprehensive neuropsychological battery for the evaluation of global cognition. The delayed memory section is a measure of delayed recall and recognition for verbal and visual information. It includes the subtests List Recall, List Recognition, Story Memory, and Figure Recall. Low scores on this index indicate difficulties with recognition and retrieval of information from long-term memory stores This index is composed of both auditory and visual measures; therefore, a severe deficit in language, auditory processing, or visual functioning may impact one of the measures more than the other. Analysis included the sum of the raw scores for each of the delayed memory subtests, with possible scores ranging from 0 to 62. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Change in Overall Fluid Cognitive Abilities
時間枠:Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Cognitive function was determined using the NIH Toolbox-Cognition Battery computerized tests, specifically the Fluid composite score. It is derived by averaging the subtests in the Fluid domain to achieve an overall standard score. Fully Corrected T-scores are adjusted for for age, gender, race/ethnicity, and educational attainment. The score compares the score of the participant to those in the NIH Toolbox nationally representative normative sampling. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Cumulative Working Memory Effects of HD-tDCS Across Treatment Sessions
時間枠:Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

The n-back test is a working memory task where participants identify stimulus that matches stimulus experienced "n" steps back. Participants performed a 2-back test, in which they were asked to remember and press a button when shown a stimulus that appeared 2 steps before the current one (e.g. square, circle, square).

The number of correct and incorrect identifications are normalized (z-score). Total score is the z-score of correct button presses minus the z-score of incorrect button presses. A higher score (d') reflects better working memory performance. Possible scores range from -4.85 to 4.85. Positive change (increase) in 2-back score across treatment sessions indicates improvement in working memory performance. Data is shown as the mean slope calculation of participants across first 5 days of treatment and across all treatments, x=days of treatment, y=n-back score.

Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Cumulative Memory Accuracy Effects of HD-tDCS Across Treatment Sessions
時間枠:Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Paired Associates task is a verbal memory task that asks participants to learn a list of word pairs. After a delay, participants are shown correct and mismatched word pairs one at a time and asked to identify if the displayed word pair was from the list they were asked to learn or not.

Total accuracy is a proportion (total correct responses divided by total trials completed) ranging from 0 to 1 that measures the accuracy of a participant's responses to both correct and mismatched word pairs. Higher scores indicate better verbal memory performance, and positive changes over time indicate an improvement in verbal memory performance, measured after baseline (Session 1) and every intervention session (Sessions 2-5)

Data is shown as the mean slope calculation of participants across first 5 days of treatment and across all treatments, x=days of treatment, y= total accuracy.

Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Cumulative Memory Sensitivity Effects of HD-tDCS Across Daily Sessions
時間枠:Baseline
Verbal memory performance for computerized Paired Associates task, summarized with a computational model (linear ballistic accumulator decision model). The model uses each participant's accuracy and reaction times across trials to estimate how efficiently they accumulate information to distinguish previously studied (target) word pairs from new (lure) pairs. Reported outcome is the average memory sensitivity score at baseline, expressed as unitless model values (scores on a scale) where higher scores indicate better discrimination, scores near zero indicate chance-level performance, and negative scores (if present) indicate performance worse than chance.
Baseline
Tolerability of HD-tDCS
時間枠:Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks); values represent mean symptom burden averaged across all post-stimulation assessments
Tolerability was assessed using the HD-tDCS Safety Questionnaire, an 11-item symptom checklist. The questionnaire assesses the presence (yes/no) of 10 specific self-reported symptoms (Itching, Burning, Tingling, Scalp Pain, Trouble Concentrating, Sleep problems, Headache, Mood Change, Neck Pain, and Other symptoms) and 1 oberserved symptom, Skin Redness. Skin Redness was excluded from this analysis as it is not related to the participant's perception of tolerability. The total score (symptom burden) was calculated by summing the number of symptoms present across the 10 items for each session. Score range: 0 to 10 symptoms, where 0 = no symptoms present and 10 = all symptoms present. Higher scores indicate worse tolerability (more symptoms experienced). Values represent the mean number of symptoms per session, calculated by averaging symptom burden scores across all post-stimulation assessments within each treatment group.
Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks); values represent mean symptom burden averaged across all post-stimulation assessments
Effectiveness of Blinding of HD-tDCS
時間枠:Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks)
Participant's perception of treatment assignment assessed after each stimulation session using a 3-category ordinal scale. Participants guessed whether they received: (0) Sham stimulation, (1) Don't Know, or (2) Active stimulation. The scale is ordinal with Sham < Don't Know < Active. Effective blinding is indicated by no significant difference in the distribution of perceived assignment between active and sham groups (i.e., participants in active groups cannot reliably distinguish their treatment from sham). Higher proportional odds ratios would indicate active group participants were more likely to guess "active"; lower ratios would indicate sham participants were more likely to guess "active" (paradoxical pattern suggesting convincing sham condition).
Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks)
Change in Default Mode Network Connectivity
時間枠:Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

The outcome focuses on default mode network (DMN) within-network functional connectivity. Within-network functional connectivity is estimated from fMRI data as strength of temporal coupling within DMN regions (nodes). For each participant and time point, correlation-based connectivity (Pearson r; Fisher r-to-z transformed; arbitrary units) was computed between DMN regions defined using a standard functional atlas. Higher values reflect stronger functional connectivity within DMN. A Z-score's range is infinite. Expected value is around -3 to 3. Analyses are conducted separately for amyloid negative (A-) and amyloid positive (A+) participants.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Cumulative Cognitive Change Across Daily Consecutive Sessions
時間枠:Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Measured through change in Cogstate or other comparable computerized cognitive testing scores across consecutive daily sessions.
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Change in Global Cognition
時間枠:Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

The Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) is a comprehensive neuropsychological battery for the evaluation of global cognition and has been validated in subjects with mild cognitive impairment, moderate to severe traumatic brain injuries, vascular dementias, and Alzheimer's disease. Data was analyzed using the sum of the subtest raw scores, which is an indicator of the general cognitive functioning of the examinee. Low scores suggest general cognitive impairment even when some individual subtest scores may be within normal limits. Individuals with low scores on this measure exhibit problems with attention, memory, language, and construction skills. Possible scores range from 0 to 321.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

その他の成果指標

結果測定
メジャーの説明
時間枠
抑制能力の変化
時間枠:ベースラインと介入後 (tDCS セッション 5 & 30 後)
NIH ツールボックス フランカー抑制制御および注意テスト スコアの変更を通じて測定するアプリオリな意図
ベースラインと介入後 (tDCS セッション 5 & 30 後)
構想力の変化
時間枠:ベースラインと介入後 (tDCS セッション 5 & 30 後)
NIH Toolbox Dimensional Change Card Sort Test Score の変化によって測定するアプリオリな意図
ベースラインと介入後 (tDCS セッション 5 & 30 後)
ピクチャ シーケンス メモリの変更
時間枠:ベースラインと介入後 (tDCS セッション 5 & 30 後)
NIH ツールボックスの画像シーケンス メモリ テスト スコアの変化を通じて測定するアプリオリな意図
ベースラインと介入後 (tDCS セッション 5 & 30 後)
ワーキングメモリー能力の変化
時間枠:ベースラインと介入後 (tDCS セッション 5 & 30 後)
NIH ツールボックス リスト ソーティング ワーキング メモリ テスト スコアの変更を通じて測定するアプリオリな意図
ベースラインと介入後 (tDCS セッション 5 & 30 後)
処理速度の変化
時間枠:ベースラインと介入後 (tDCS セッション 5 & 30 後)
NIH ツールボックス パターン比較処理速度テスト スコアの変化を通じて測定するアプリオリな意図
ベースラインと介入後 (tDCS セッション 5 & 30 後)
視空間機能の変化
時間枠:ベースラインと介入後 (tDCS セッション 5 & 30 後)
RBANS 視覚空間インデックス スコアの変化によって測定
ベースラインと介入後 (tDCS セッション 5 & 30 後)
言語機能の変化
時間枠:ベースラインと介入後 (tDCS セッション 5 & 30 後)
RBANS 言語インデックス スコアの変化によって測定
ベースラインと介入後 (tDCS セッション 5 & 30 後)
注意の変化
時間枠:ベースラインと介入後 (tDCS セッション 5 & 30 後)
RBANS Attention Index スコアの変化によって測定
ベースラインと介入後 (tDCS セッション 5 & 30 後)
記憶機能の変化
時間枠:ベースラインと介入後 (tDCS セッション 5 & 30 後)
RBANS Immediate Memory Index スコアの変化によって測定
ベースラインと介入後 (tDCS セッション 5 & 30 後)
認知機能の変化
時間枠:ベースラインと介入後 (tDCS セッション 5 & 30 後)
RBANS サブテストのスコアの変化を通じて測定するアプリオリな意図
ベースラインと介入後 (tDCS セッション 5 & 30 後)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Benjamin Hampstead, PhD、Associate professor

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年4月1日

一次修了 (実際)

2024年12月6日

研究の完了 (実際)

2024年12月19日

試験登録日

最初に提出

2019年3月11日

QC基準を満たした最初の提出物

2019年3月13日

最初の投稿 (実際)

2019年3月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月2日

QC基準を満たした最後の更新が送信されました

2026年6月29日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • HUM00146180
  • 1R01AG058724 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する